TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Crohn's disease (CD) for at least 90 days.~2. Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450.~3. Subject inadequately responded to or experienced intolerance to previous treatment with immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate) and/or anti-TNF agent (e.g., infliximab, adalimumab, or certolizumab pegol).~Exclusion Criteria:~1. Subjects with ulcerative colitis (UC), collagenous colitis or indeterminate colitis.~2. Subject who has had surgical bowel resections in the past 6 months or is planning resection.~3. Subjects with an ostomy or ileoanal pouch.~4. Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.~5. Subject who has short bowel syndrome.~6. Subject with recurring infections or active Tuberculosis (TB).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Induction Period ABT-494 Twice Daily Medium/High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
- Extension Phase ABT-494 High Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 High Dose orally dosed twice a day
- Induction Period Placebo (Type: PLACEBO_COMPARATOR): Induction Period Placebo orally dosed twice a day
- Induction Period ABT-494 Low Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Low Dose orally dosed twice a day
- Induction Period ABT-494 Once Daily Medium/High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
- Extension Phase ABT-494 Low Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 Low Dose orally dosed twice a day
- Induction Period ABT-494 High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 High Dose orally dosed twice a day
- Induction Period ABT-494 Low/Medium Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
- Extension Phase ABT-494 Medium Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 Medium Dose orally dosed twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of OCD by DSM-IV~* Age 18-65~* Y-BOCS greater than 20~* Written informed consent~* Females of childbearing potential must have a negative serum or urinary beta-HCG test.~Exclusion Criteria:~* Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.~* Patients who, in the investigator's judgment, pose a serious suicidal or homicidal risk.~* Serious or unstable medical illness including cardiovascular (including hypertension), hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.~* History of seizure disorder~* Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder~* If there is a history of substance abuse, patients in remission at least 6 months.~* Currently being treated with behavioral therapy, specifically exposure and response prevention, for OCD.~* Other medications for medical disorders that may interfere with duloxetine~* Current major depression or prescribed an antidepressant for major depression within the past 12 months. We will assess depressive symptoms with the BDI throughout the course of the study in order to assess subsyndromal depressive symptoms and to assess for the emergence of depressive symptoms.~* Taken other psychotropic medication within 2 weeks of beginning the study (4 weeks for fluoxetine).~* More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another SSRI in the past.~* Known hypersensitivity to duloxetine or any of the inactive ingredients.~* Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or potential need to use an MAOI drug during the study or within 5 days of discontinuation of study drug.~* Patients with uncontrolled narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- All Study Participants (Type: EXPERIMENTAL): Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have provided a signed Informed Consent Form~* ECOG performance status of 0-1~* BMI ≥ 18.5~* Age: 18-65 years old~* Histologically confirmed diagnosis of metastatic pancreatic cancer~* No prior palliative chemotherapy~* Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria~* Life expectancy ≥ 3 months~* Patient has adequate bone marrow and organ function~  * Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L~ * Platelets ≥ 90 x 109/L~ * Hemoglobin ≥ 90 g/L~* Patient has adequate liver function~  * AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis)~ * Serum bilirubin ≤ 1.2 x ULN~* Creatinine ≤ 1.25 times ULN~* Good compliance~Exclusion Criteria:~* Pregnant or lactating women~* Brain metastasis or only with bone metastasis.~* Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions.~* Refuse to take appropriate contraceptive measures (including male patients).~* Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.~* Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases.~* Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).~* Psychiatric illness that would prevent the patient from giving informed consent.~* Patient is concurrently using other antineoplastic agent~* Patient has used investigational antineoplastic agent within 4 weeks prior to entry.~* Known HIV-positivity.~* No history of chronic diarrhea, nausea or vomit.~* No ≥ grade 2 sensory peripheral neuropathy.~* A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina.~* Infectious disease or inflammation with body temperature ≥ 38 ℃.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- FOLFIRINOX (Type: EXPERIMENTAL): Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed CLL or SLL and satisfying at least 1 of the following criteria for requiring treatment:~   * Progressive splenomegaly and/or lymphadenopathy identified by physical examination or radiographic studies~  * Anemia (\<11 g/dL) or thrombocytopenia (\<100,000/μL) due to bone marrow involvement~  * Presence of unintentional weight loss \> 10% over the preceding 6 months~  * NCI CTCAE Grade 2 or 3 fatigue~  * Fevers \> 100.5° or night sweats for \> 2 weeks without evidence of infection~  * Progressive lymphocytosis with an increase of \> 50% over a 2 month period or an anticipated doubling time of \< 6 months~2. 1 to 3 prior treatment regimens for CLL/SLL~3. ECOG performance status of ≤ 1~4. ≥ 18 years of age~5. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty~6. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations)~Exclusion Criteria:~1. Any chemotherapy, therapeutic antineoplastic antibodies (not including radio- or toxin immunoconjugates), radiation therapy, or experimental antineoplastic therapy within 4 weeks of first dose of study drug~2. Radio- or toxin-conjugated antibody therapy within 10 weeks of first dose of study drug~3. Concomitant use of medicines known to cause QT prolongation or torsades de pointes~4. Transformed lymphoma or Richter's transformation Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk~5. Any of the following laboratory abnormalities: oAbsolute neutrophil count (ANC) \< 1000 cells/mm3 (1.0 x 109/L) oPlatelet count \< 50,000/mm3 (50 x 109/L) oSerum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x upper limit of normal (ULN) oCreatinine \> 2.0 x ULN or creatinine clearance \< 40 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR) (Type: EXPERIMENTAL): None
- PCI-32765 plus bendamustine/rituximab (BR) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HW006 LATERAL Thoracotomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be ≥19 years of age at time of informed consent to participate in the Intermacs® registry.~2. Subject receives a HeartWare HVAD (The device should be the subject's first VAD implant).~3. Subject signed an Intermacs® informed consent if required by local IRB policy.~4. Subject signed a HeartWare informed consent.~Exclusion Criteria:~1. Subject is incarcerated (prisoner).~2. Subject did not sign the informed consent at sites where waiver of consent was not granted.~3. Body Surface Area (BSA) \< 1.2 m\^2.~4. Prior cardiac transplant or cardiomyoplasty.~5. Subject is receiving a BiVAD.~6. Subject is receiving the device as an RVAD.~7. Subject data is generated from non- Intermacs® centers.~8. Pediatric subjects (\< 19 years of age).~9. Subjects who receive a temporary LVAD~10. Subjects whose device strategy is listed as Destination Therapy at the time of implant.~11. Severe Right Heart failure~12. Aortic insufficiency or mechanical aortic valve.~13. Planned concomitant procedure (e.g.valve repair or replacement, CABG, septal defect repair).~14. Known LV Thrombus.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HeartWare HVAD via Thoracotomy (Type: EXPERIMENTAL): HeartWare HVAD implanted via thoracotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a new prescription for an oral anticoagulant that had a diagnosis of atrial fibrillation or atrial flutter within the 3 years prior to the date of the prescription~* Patients aged 18 years or older (except Alberta, Nova Scotia, and Ontario, where patients will be aged at least 66 years or older)~Exclusion Criteria:~* Patients with less than one year of data availability prior to cohort entry~* Patients with a diagnosis of valvular disease (including rheumatic heart disease) or prior cardiac valve surgery~* Patients with a diagnosis of venous thromboembolic disease in the year prior to cohort entry~* Patients who underwent hemodialysis in the 90 days prior to cohort entry~* Patients with a hip, femur, or knee surgery in the 30 days prior to cohort entry~* Patients with a diagnosis of antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Direct oral anticoagulants (DOACs) (Type: None): Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
- Warfarin (Type: None): Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged between 50 and 75.~* Outpatients scheduled for screening or surveillance colonoscopy for polyps or colorectal cancer )~* Able to comprehend the full nature and purpose of the study, including possible risks and side effects.~* Able to co-operate with the investigator and to comply with the requirements of the entire study.~* Signed written informed consent prior to inclusion in the study.~Exclusion Criteria:~* Patients at high risk of colorectal cancer e.g. ulcerative colitis~* Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.~* Previous medical history of, or suspected hypersensitivity to, the PEG based bowel cleansing preparation and/or bowel cleansing formulations' ingredients.~* Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Methylene Blue MMX® 200mg (Type: ACTIVE_COMPARATOR): Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
- Methylene Blue MMX® 100mg (Type: ACTIVE_COMPARATOR): Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
- Placebo (Type: PLACEBO_COMPARATOR): Oral dose, 8 Placebo tablets over a 4hr schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of unresectable State III or IV malignant melanoma (excluding ocular melanoma); A pre- and post-treatment fresh core or excision tumor biopsy must be provided.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1 (Type: ACTIVE_COMPARATOR): None
- A2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* over the legal age (21years old) to drink alcohol.~Exclusion Criteria:~* Volunteers will be excluded from the study if they suffer from any of the following conditions:~Alcoholism, Diabetes, Kidney/bladder stones, Kidney disease, Liver disease, Stomach ulcer, Organ transplant patients, Dialysis patients, and patients with alcohol allergies.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- all study participants (Type: EXPERIMENTAL): subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cancer, admitted for myelosupppresive stem cell transplantation. Included preparative regimens include: TBI/VP16/CY, TBI/CY, BU/CY (PO \& IV), and BCV~* Age 18 or older~* Alcohol intake \<100 gm/d for the last year (\< approximately 5 drinks per day)~* Renal function: estimated or measured CrCl 50 ml/min~* Liver function: T.Bili \<1.5, AST \< 2x ULN, unless due to disease~* Able to swallow tablets and capsules~Exclusion Criteria:~* Age \< 18~* High alcohol intake \[\> 100 gm/d in the last year\]~* Allergy or intolerance to: ondansetron or dexamethasone~* Renal dysfunction \[measured or estimated CrCl \< 50 ml/min\]~* Liver dysfunction \[T.Bili \> 1.5, AST \> 2x ULN, unless due to disease\]~* Inability to swallow tablets or capsules~* Concurrent condition requiring systemic steroid use~* Nonmyeloablative SCT, patients receiving the conditioning regimens not included \[see inclusion criteria\]~* History of anticipatory nausea and vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard PO (Zofran + Dexamethasone) (Type: PLACEBO_COMPARATOR): Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
- Aprepitant (MK-869) + Standard PO (Type: ACTIVE_COMPARATOR): Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete